COMP <GO>
VKTX vs PBLS // FREE CASH FLOW YIELD
Viking Therapeutics Inc. (NASDAQ) VS. Parabilis Medicines Inc. (NASDAQ) • 15-METRIC TALLY: VKTX 0
— PBLS 2
■ METRIC PARITY
LAST: $26.86 (+5.92%) • MKT CAP: $3.38B
fcf-yield
-8.25%
LAST: $28.70 (+1.88%) • MKT CAP: $3.50B
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. PBLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | PBLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -8.25% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.02 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.5 | 48.5 | -1.99 | PBLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $3.50B | -$124.0M | PBLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | PBLS REV | VKTX GROSS % | PBLS GROSS % | VKTX FCF | PBLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$278.7M | — |
| FY 2024 | $0 | — | — | — | -$87.8M | — |
| FY 2023 | $0 | — | — | — | -$73.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
PBLS // BETA —